

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Rabbit Anti-VEGF Receptor 2, phospho (Tyr1175) Monoclonal Antibody, Unconjugated, Clone D5B11

RRID:AB_1642326

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3770, RRID:AB_1642326

Antibody Information

URL: http://antibodyregistry.org/AB_1642326

Proper Citation: Cell Signaling Technology Cat# 3770, RRID:AB_1642326

Target Antigen: KDR

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10428262, AB_1642326, AB_2132355.

Antibody Name: Rabbit Anti-VEGF Receptor 2, phospho (Tyr1175) Monoclonal Antibody, Unconjugated, Clone D5B11

Description: This monoclonal targets KDR

Target Organism: mouse, human

Antibody ID: AB_1642326

Vendor: Cell Signaling Technology

Catalog Number: 3770

Record Creation Time: 20250820T001754+0000

Record Last Update: 20250820T075408+0000

Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-VEGF Receptor 2, phospho (Tyr1175) Monoclonal Antibody, Unconjugated, Clone D5B11.

No alerts have been found for Rabbit Anti-VEGF Receptor 2, phospho (Tyr1175) Monoclonal Antibody, Unconjugated, Clone D5B11.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wittig F, et al. (2024) ??-Caryophyllene Inhibits Endothelial Tube Formation by Modulating the Secretome of Hypoxic Lung Cancer Cells-Possible Role of VEGF Downregulation. International journal of molecular sciences, 25(2).

Wittig F, et al. (2023) Antiangiogenic Action of JZL184 on Endothelial Cells via Inhibition of VEGF Expression in Hypoxic Lung Cancer Cells. Cells, 12(19).

Lam YT, et al. (2020) Androgens Stimulate EPC-Mediated Neovascularization and Are Associated with Increased Coronary Collateralization. Endocrinology, 161(5).

Lien JC, et al. (2019) A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling. British journal of pharmacology, 176(20), 4034.